Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago
In this edition:
1. Zoledronic …
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin
In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy …
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna
In this edition:
Bevacizumab and Survival in Metastatic Breast Cancer
Source: N Engl J Med 357:26
George Canellos, Dana-Farber Cancer Institute, Boston
Progresson-free survival, but not overall survival, was …
Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question
 David Cameron |  Martine Piccart |  Eric Van Cutsem |
 Jim Cassidy |  Volker Heinemann |
REFERENCE: ESMO 2006, Abstract: 141O
David Cameron, Western General Hospital, Edinburgh
COMMENT: Martine Piccart, Jules
